top of page

Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24

ORLANDO, FL / ACCESSWIRE / October 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24. The Company's presentation will be on ‘Improving existing transdermal technologies to reduce the liability profile of abusable medications' which will discuss our AVERSA technology as a reference point. Nutriband CEO, Gareth Sheridan, will be speaking on behalf of the Company.

The Company was also invited to participate as a panelist for a discussion to take place on the topic of microneedles as a therapeutic tool, to be moderated by James Birchall, Professor of Pharmaceutical Sciences, Cardiff University. Nutriband COO and President of its 4P Therapeutics subsidiary, Dr. Alan Smith, will be participating as a panelist on the Company's behalf.

The panel discussion overview will be as follows:

Reviewing microneedles technologies as a novel therapeutic tool for drug delivery

  • Discussing the benefits of microneedle patches and transdermal delivery systems

  • Understanding the challenges associated with microneedle technologies

  • Dissecting the latest trends in microneedle drug delivery

Conference presentations and panelists are also expected from Merck (NYSE: MRK), GSK (NYSE: GSK), Sanofi (NASDAQ: SNY), Rani Therapeutics (NASDAQ: RANI), Leo Pharmaceuticals, Vaxxas and Starton Therapeutics.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA ® technology. Aversa is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.

The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2022 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. 


bottom of page